Sponsors (2)
The bill strengthens national security by blocking and closely overseeing potentially risky biotech vendors in federal procurement, but it creates costs, legal/market uncertainty, and potential disruptions to research, health care, and affected businesses.
Federal agencies will reduce supply-chain and foreign-adversary risks by banning procurement of covered biotechnology equipment and services from designated companies, lowering risks to federal operations and national security.
Federal employees, contractors, and critical missions will retain necessary access because a waiver process (with OMB oversight and reporting) plus explicit exemptions for authorized intelligence and Title V activities allow continued use for emergencies, national security, and essential health responses.
Taxpayers and federal employees will gain greater transparency and oversight because agencies must publish, justify, and periodically review the list of designated risky biotech vendors.
Scientists, researchers, hospitals, and patients (particularly those with chronic conditions) may face procurement restrictions or delays for sequencing, data services, or multiomic tools, which could hamper research progress and patient care.
Government contractors, grant recipients, and small biotech firms could lose contracts or funding and suffer immediate economic and operational harm if their services are designated as disallowed for procurement.
Vendors, researchers, and investors will face legal and market uncertainty because broad definitions of covered services and OMB's discretionary designation authority could unpredictably bar suppliers from government contracting and cause reputational harm before public notice.
Based on analysis of 2 sections of legislative text.
Blocks federal agencies and federal grant/loan-funded purchases from using biotech equipment or services from designated "companies of concern," with staged effective dates and limited waivers.
Introduced December 11, 2025 by Gary C. Peters · Last progress December 11, 2025
Prohibits executive agencies from buying or using biotechnology equipment or services made or provided by designated "biotechnology companies of concern." It also bars agencies from contracting with, and from obligating federal loan or grant funds to, entities that use such covered equipment or services acquired after a specified effective date. The prohibitions take effect in stages after a required revision to the Federal Acquisition Regulation (FAR) and include a five-year transitional exception for pre-existing contracts, plus case-by-case waivers and a safe-harbor for items no longer produced by a listed company.